• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround

But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
By KEVIN CURRAN May 02, 2019 | 01:02 PM EDT
Stocks quotes in this article: TEVA, LLY, AMGN

Teva Pharmaceuticals (TEVA) , one of the world's largest drug manufacturers, is still on track to recover from its "trough year" in 2020, according to CEO Kare Schultz.

Shares of the Israel-based pharmaceutical company slipped again on Thursday after the company reported mixed earnings results, stung by disappointing revenue figures as the company's flagship MS drug Copaxone continues to erode amidst generic competition.

"The challenge has been that Copaxone was a real blockbuster," Schultz told Real Money, explaining that as generic competition has picked up, this status has faded.

However, Schultz was quick to point out that his restructuring plan, aimed at delevering the company, should provide a path forward through new drugs like migraine drug Ajovy and Tardive dyskinesia drug Austedo should curtail these losses in the long run.

"We are projected to lose about $3 billion from Copaxone, so we need to take out costs to mitigate that," he explained. "Once we cut costs at that level we can focus on Ajovy and Austedo."

The company has indeed been effective at reducing its debt load in recent years, cutting its indebtedness from $35.8 billion at the start of 2017 to $28.6 billion at the close of the first quarter 2019.

Still, further progress of this cost reduction trend will need to be seen before analysts are ready to call for any inflection point.

"The continued progress with cost reductions should help mitigate some concerns about the company's ability to deliver on that metric as some of the lower hanging fruit may be gone," Credit Suisse analyst Dr. Vamil Divan commented. "Given the significant weakness the stock has seen in the past two months, today's results may be seen as a relief, but overall we do not think they represent a fundamental change in the story as we continue to look for signs of greater top line growth to supplement the expected cost reductions and get us more enthusiastic on the name."

About the roadmap ahead for the company's newest releases, Ajovy and Austedo, analysts were largely encouraged.

"We are very, very happy about the progress of Ajovy, and we do very much look forward to launching this great product, which helps people with chronic migraine in Europe," Schultz told analysts on Thursday morning.

Schultz explained in an interview with RM that the clinical results thus far are also encouraging, leaving the company poised to gain market share from key competitors like Amgen (AMGN) and Eli Lilly (LLY) .

"Ajovy is the first critical breakthrough in chronic migraines in 20 years," Schultz said. "The need is there."

Similarly, he expects Austedo to provide solid results in coming years as Copaxone falls out of favor.

"In Tardive dyskinesia, there's huge unmet need," he explained. "If you look at these TRx accounts per quarter, then you compare it to that Tardive dyskinesia alone, there's probably 500,000 patients in the U.S. suffering from this condition. They have had no real efficacious therapy before, but with this drug, they now have a drug that's indicated for it."

The company now expects about $350 million in revenue from the drug in 2019 as adoption ramps.

"We are completely on track for 2020," Schultz concluded. "The company will be better off next year, maybe not dramatically better off, but better off."

(Amgen is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells AMGN? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Restructuring | Debt Financing | Drug Approvals | Earnings | Investing | Stocks | World | Healthcare | Pharmaceuticals | Analyst Actions

More from Stocks

Bearish Bets: 3 Stocks You Should Think About Shorting This Week

Bob Lang
Jun 26, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

For Smith & Wesson, Load, Cock and Fire Another Round

Bret Jensen
Jun 26, 2022 7:30 AM EDT

Here's how to aim for this gunmaker once more with a covered-call play.

Does the Big Bounce Mean More to Come? Let's See What Drove the Move

James "Rev Shark" DePorre
Jun 24, 2022 4:42 PM EDT

Much of the rally can be attributed to structural reasons, not fundamentals, technicals, or even macro ones.

MongoDB Is Poised for a Rally

Bruce Kamich
Jun 24, 2022 2:15 PM EDT

Here's our initial upside price target for MDB which provides a general purpose database platform.

See That Down the Road? It's the Big 'Green' Bubble, Ready to Pop

Jim Collins
Jun 24, 2022 1:30 PM EDT

Environmental, social, and corporate governance has created a monster and gullible investors should hit the brakes on their EVs and run from the Washington technocrats while they have the chance.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:19 PM EDT PAUL PRICE

    Two Good Signs Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login